Stay updated on LowDose IL-2 & Pembrolizumab in Melanoma/RCC Clinical Trial
Sign up to get notified when there's something new on the LowDose IL-2 & Pembrolizumab in Melanoma/RCC Clinical Trial page.

Latest updates to the LowDose IL-2 & Pembrolizumab in Melanoma/RCC Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedFooter revision updated to v3.6.5, representing a site update/version bump. No changes to the study details, eligibility criteria, or results are introduced.SummaryDifference0.1%

- Check27 days agoNo Change Detected
- Check34 days agoChange DetectedThe page shows a new revision number (v3.6.4) indicating a recent update to the ClinicalTrials.gov record. No study details or terms appear to be changed in the visible context.SummaryDifference0.1%

- Check55 days agoChange DetectedThe page footer now shows Revision: v3.6.3, replacing Revision: v3.6.2. This indicates the page has been updated to a newer revision.SummaryDifference0.1%

- Check63 days agoChange DetectedThe page's revision tag was updated from v3.6.0 to v3.6.2, signaling a backend or template update. This update does not modify the study content or user-facing information on the page.SummaryDifference0.1%

- Check77 days agoChange DetectedAdded new help/navigation sections (How to Read a Study Record, Common Questions, How to Join a Study) and updated the Intervention/Treatment heading; the old Intervention / Treatment label and the previous Revision note (Revision: v3.5.5) were removed, aligning with the new v3.6.0 revision.SummaryDifference0.5%

- Check84 days agoChange DetectedRevision label on the page changes from v3.5.4 to v3.5.5. This reflects a metadata/version update and does not alter the visible content.SummaryDifference0.1%

Stay in the know with updates to LowDose IL-2 & Pembrolizumab in Melanoma/RCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the LowDose IL-2 & Pembrolizumab in Melanoma/RCC Clinical Trial page.